ASX - By Stock
|
NOX |
Re:
Ann: New Executive Appointments and Board Change
|
|
pohutukawa
|
25 |
9.0K |
8 |
16/10/19 |
16/10/19 |
ASX - By Stock
|
25
|
9.0K
|
8
|
|
ASX - By Stock
|
NOX |
Re:
Ann: LuPIN Trial Demonstrates High Rates of Response
|
|
pohutukawa
|
33 |
17K |
1 |
15/10/19 |
15/10/19 |
ASX - By Stock
|
33
|
17K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Amended/Departure of Dr Van Wyk
|
|
pohutukawa
|
8 |
4.7K |
7 |
25/09/19 |
25/09/19 |
ASX - By Stock
|
8
|
4.7K
|
7
|
|
ASX - By Stock
|
NOX |
Re:
St Vincent’s Hospital LUPIN Study PR
|
|
pohutukawa
|
33 |
16K |
6 |
26/07/19 |
26/07/19 |
ASX - By Stock
|
33
|
16K
|
6
|
|
ASX - By Stock
|
KZA |
Re:
Dr James Garner discusses Kazia's Phase 2 trial in glioblastoma with Proactive Investors
|
|
pohutukawa
|
20 |
6.5K |
0 |
08/05/19 |
08/05/19 |
ASX - By Stock
|
20
|
6.5K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
Dr James Garner discusses Kazia's Phase 2 trial in glioblastoma with Proactive Investors
|
|
pohutukawa
|
20 |
6.5K |
1 |
08/05/19 |
08/05/19 |
ASX - By Stock
|
20
|
6.5K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: KZA: Kazia sells stake in Noxopharm
|
|
pohutukawa
|
7 |
10K |
8 |
21/03/19 |
21/03/19 |
ASX - By Stock
|
7
|
10K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
SP
|
|
pohutukawa
|
61 |
29K |
9 |
01/03/19 |
01/03/19 |
ASX - By Stock
|
61
|
29K
|
9
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda and Radiotherapy Delivers Clinical Benefits
|
|
pohutukawa
|
22 |
7.3K |
2 |
06/02/19 |
06/02/19 |
ASX - By Stock
|
22
|
7.3K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda and Radiotherapy Delivers Clinical Benefits
|
|
pohutukawa
|
22 |
7.3K |
1 |
06/02/19 |
06/02/19 |
ASX - By Stock
|
22
|
7.3K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Veyonda and Radiotherapy Delivers Clinical Benefits
|
|
pohutukawa
|
22 |
7.3K |
4 |
06/02/19 |
06/02/19 |
ASX - By Stock
|
22
|
7.3K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Appendix 4C - Quarterly
|
|
pohutukawa
|
9 |
3.6K |
2 |
30/01/19 |
30/01/19 |
ASX - By Stock
|
9
|
3.6K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Abstract GDC-0084 Inhibits CSCC cell growth
|
|
pohutukawa
|
76 |
26K |
2 |
25/01/19 |
25/01/19 |
ASX - By Stock
|
76
|
26K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
When will we reach parity with our 5% cousins
|
|
pohutukawa
|
37 |
11K |
1 |
25/01/19 |
25/01/19 |
ASX - By Stock
|
37
|
11K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
When will we reach parity with our 5% cousins
|
|
pohutukawa
|
37 |
11K |
1 |
11/01/19 |
11/01/19 |
ASX - By Stock
|
37
|
11K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: AGM presentations
|
|
pohutukawa
|
22 |
5.9K |
5 |
08/11/18 |
08/11/18 |
ASX - By Stock
|
22
|
5.9K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Beware the false prophet
|
|
pohutukawa
|
41 |
14K |
1 |
30/10/18 |
30/10/18 |
ASX - By Stock
|
41
|
14K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Beware the false prophet
|
|
pohutukawa
|
41 |
14K |
1 |
29/10/18 |
29/10/18 |
ASX - By Stock
|
41
|
14K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Annual Report to shareholders
|
|
pohutukawa
|
8 |
4.6K |
5 |
28/09/18 |
28/09/18 |
ASX - By Stock
|
8
|
4.6K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Annual Report to shareholders
|
|
pohutukawa
|
8 |
4.6K |
2 |
28/09/18 |
28/09/18 |
ASX - By Stock
|
8
|
4.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
NYX-330
|
|
pohutukawa
|
4 |
3.9K |
5 |
31/08/18 |
31/08/18 |
ASX - By Stock
|
4
|
3.9K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Interim NOX66 Radiotherapy Clinical Data
|
|
pohutukawa
|
27 |
12K |
1 |
10/08/18 |
10/08/18 |
ASX - By Stock
|
27
|
12K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Interim NOX66 Radiotherapy Clinical Data
|
|
pohutukawa
|
27 |
12K |
6 |
08/08/18 |
08/08/18 |
ASX - By Stock
|
27
|
12K
|
6
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Interim NOX66 Radiotherapy Clinical Data
|
|
pohutukawa
|
27 |
12K |
4 |
08/08/18 |
08/08/18 |
ASX - By Stock
|
27
|
12K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia files shelf registration statement with SEC
|
|
pohutukawa
|
16 |
5.1K |
1 |
20/07/18 |
20/07/18 |
ASX - By Stock
|
16
|
5.1K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia files shelf registration statement with SEC
|
|
pohutukawa
|
16 |
5.1K |
2 |
20/07/18 |
20/07/18 |
ASX - By Stock
|
16
|
5.1K
|
2
|
|
ASX - By Stock
|
KZA |
Re:
Share price
|
|
pohutukawa
|
79 |
20K |
10 |
25/06/18 |
25/06/18 |
ASX - By Stock
|
79
|
20K
|
10
|
|
ASX - By Stock
|
NOX |
Re:
Ann: End-of-Study Clinical Data shows benefit of NOX66
|
|
pohutukawa
|
1 |
1.8K |
4 |
05/06/18 |
05/06/18 |
ASX - By Stock
|
1
|
1.8K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Press Coverage
|
|
pohutukawa
|
104 |
27K |
3 |
01/06/18 |
01/06/18 |
ASX - By Stock
|
104
|
27K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Kazia pos.,/ neg.,
|
|
pohutukawa
|
24 |
7.8K |
8 |
16/05/18 |
16/05/18 |
ASX - By Stock
|
24
|
7.8K
|
8
|
|
ASX - By Stock
|
KZA |
Re:
KAZIA
|
|
pohutukawa
|
78 |
30K |
3 |
09/04/18 |
09/04/18 |
ASX - By Stock
|
78
|
30K
|
3
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX Mid-Year Briefings
|
|
pohutukawa
|
16 |
9.3K |
2 |
07/04/18 |
07/04/18 |
ASX - By Stock
|
16
|
9.3K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX Mid-Year Briefings
|
|
pohutukawa
|
16 |
9.3K |
1 |
07/04/18 |
07/04/18 |
ASX - By Stock
|
16
|
9.3K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: NOX Mid-Year Briefings
|
|
pohutukawa
|
16 |
9.3K |
4 |
07/04/18 |
07/04/18 |
ASX - By Stock
|
16
|
9.3K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
KAZIA
|
|
pohutukawa
|
78 |
30K |
0 |
07/04/18 |
07/04/18 |
ASX - By Stock
|
78
|
30K
|
0
|
|
ASX - By Stock
|
KZA |
Re:
KAZIA
|
|
pohutukawa
|
78 |
30K |
1 |
07/04/18 |
07/04/18 |
ASX - By Stock
|
78
|
30K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
KAZIA
|
|
pohutukawa
|
78 |
30K |
1 |
28/03/18 |
28/03/18 |
ASX - By Stock
|
78
|
30K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presentation to Proactive Investors CEO series
|
|
pohutukawa
|
79 |
28K |
3 |
23/03/18 |
23/03/18 |
ASX - By Stock
|
79
|
28K
|
3
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia presentation to Proactive Investors CEO series
|
|
pohutukawa
|
79 |
28K |
2 |
23/03/18 |
23/03/18 |
ASX - By Stock
|
79
|
28K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
ESMO Presentation
|
|
pohutukawa
|
24 |
11K |
1 |
07/03/18 |
07/03/18 |
ASX - By Stock
|
24
|
11K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
ESMO Presentation
|
|
pohutukawa
|
24 |
11K |
5 |
06/03/18 |
06/03/18 |
ASX - By Stock
|
24
|
11K
|
5
|
|
ASX - By Stock
|
NOX |
Re:
ESMO Presentation
|
|
pohutukawa
|
24 |
11K |
4 |
06/03/18 |
06/03/18 |
ASX - By Stock
|
24
|
11K
|
4
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Appendix 4D and Half Year Accounts
|
|
pohutukawa
|
26 |
10K |
1 |
24/02/18 |
24/02/18 |
ASX - By Stock
|
26
|
10K
|
1
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Appendix 4D and Half Year Accounts
|
|
pohutukawa
|
26 |
10K |
4 |
24/02/18 |
24/02/18 |
ASX - By Stock
|
26
|
10K
|
4
|
|
ASX - By Stock
|
KZA |
Re:
Next stop
|
|
pohutukawa
|
86 |
18K |
2 |
04/01/18 |
04/01/18 |
ASX - By Stock
|
86
|
18K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Written Opinion of the International Search Authority
|
|
pohutukawa
|
26 |
14K |
5 |
30/11/17 |
30/11/17 |
ASX - By Stock
|
26
|
14K
|
5
|
|
ASX - By Stock
|
KZA |
Re:
Ann: Kazia clarifies media report
|
|
pohutukawa
|
133 |
37K |
2 |
24/11/17 |
24/11/17 |
ASX - By Stock
|
133
|
37K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Promising Interim Clinical Data for NOX66
|
|
pohutukawa
|
17 |
8.6K |
2 |
20/11/17 |
20/11/17 |
ASX - By Stock
|
17
|
8.6K
|
2
|
|
ASX - By Stock
|
NOX |
Re:
Ann: Promising Interim Clinical Data for NOX66
|
|
pohutukawa
|
17 |
8.6K |
1 |
20/11/17 |
20/11/17 |
ASX - By Stock
|
17
|
8.6K
|
1
|
|
ASX - By Stock
|
KZA |
Re:
Cantrixel Assets Given Away for a 10% Shareholding?
|
|
pohutukawa
|
7 |
2.6K |
2 |
18/11/17 |
18/11/17 |
ASX - By Stock
|
7
|
2.6K
|
2
|
|